Katherine H Saunders1, Leon I Igel2, Monica Saumoy3, Reem Z Sharaiha3, Louis J Aronne2. 1. Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY, 10065, USA. kph2001@med.cornell.edu. 2. Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY, 10065, USA. 3. Divison of Gastroenterology and Hepatology, Weill Cornell Medicine, 1305 York Avenue, 4th Floor, New York, NY, 10021, USA.
Abstract
PURPOSE OF REVIEW: In this review, we describe the FDA-approved and investigational devices and endoscopic bariatric therapies for the treatment of obesity. We focus on literature published in the past few years and present mechanisms of action as well as efficacy and safety data. RECENT FINDINGS: Devices and endoscopic procedures are emerging options to fill the significant treatment gap in the management of obesity. Not only are these devices and procedures minimally invasive and reversible, but they are potentially more effective than antiobesity medications, often safer for poor surgical candidates and possibly less expensive than bariatric surgery. As many patients require a variety of management strategies (medications, devices, procedures, and/or surgery) in addition to lifestyle modifications to achieve clinically significant weight loss, the future of obesity treatment involves a multidisciplinary approach. Combinations of advanced treatment strategies can lead to additive or synergistic weight loss. This is an area that requires further investigation.
PURPOSE OF REVIEW: In this review, we describe the FDA-approved and investigational devices and endoscopic bariatric therapies for the treatment of obesity. We focus on literature published in the past few years and present mechanisms of action as well as efficacy and safety data. RECENT FINDINGS: Devices and endoscopic procedures are emerging options to fill the significant treatment gap in the management of obesity. Not only are these devices and procedures minimally invasive and reversible, but they are potentially more effective than antiobesity medications, often safer for poor surgical candidates and possibly less expensive than bariatric surgery. As many patients require a variety of management strategies (medications, devices, procedures, and/or surgery) in addition to lifestyle modifications to achieve clinically significant weight loss, the future of obesity treatment involves a multidisciplinary approach. Combinations of advanced treatment strategies can lead to additive or synergistic weight loss. This is an area that requires further investigation.
Authors: Bryan J Sandler; Roberto Rumbaut; C Paul Swain; Gustavo Torres; Luis Morales; Lizcelly Gonzales; Sarah Schultz; Mark Talamini; Santiago Horgan Journal: Surg Endosc Date: 2011-04-13 Impact factor: 4.584
Authors: Reem Z Sharaiha; Nikhil A Kumta; Monica Saumoy; Amit P Desai; Alex M Sarkisian; Andrea Benevenuto; Amy Tyberg; Rekha Kumar; Leon Igel; Elizabeth C Verna; Robert Schwartz; Christina Frissora; Alpana Shukla; Louis J Aronne; Michel Kahaleh Journal: Clin Gastroenterol Hepatol Date: 2016-12-23 Impact factor: 11.382
Authors: Gontrand Lopez-Nava; Reem Z Sharaiha; Eric J Vargas; Fateh Bazerbachi; Galvao Neto Manoel; Inmaculada Bautista-Castaño; Andres Acosta; Mark D Topazian; Manpreet S Mundi; Nikhil Kumta; Michel Kahaleh; Andrea Marie Herr; Alpana Shukla; Louis Aronne; Christopher J Gostout; Barham K Abu Dayyeh Journal: Obes Surg Date: 2017-10 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Andres Acosta; Michael Camilleri; Manpreet S Mundi; Elizabeth Rajan; Mark D Topazian; Christopher J Gostout Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382
Authors: J C Espinós; R Turró; G Moragas; A Bronstone; J N Buchwald; F Mearin; A Mata; H Uchima; J Turró; S Delgado-Aros Journal: Obes Surg Date: 2016-05 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427